Stroke Current Research

Disease of the small blood vessels in the brain (cerebral small vessel disease or SVD) causes a quarter of all strokes (lacunar stroke) and is the most common cause of vascular dementia. Despite its importance we understand relatively little about what causes this disease.  However we know genetic factors are important. If we can identify the responsible genes it will provide new insights into what causes SVD, and may help us identify new possible treatments.  

We are leading a worldwide collaboration to identify new genes for lacunar stroke. To identify new genes requires us to collect many thousands of cases of lacunar stroke, with the diagnosis confirmed on MRI. In a previous study, DNA lacunar 1, we collected 1000 cases. Using this data we have recently carried out an analysis which identified 11 new genes for SVD, and has provided completely new insights into what causes the disease. 

We are now extending this work aiming for a target of 5000 cases worldwide.

PI: Dr Sandeep Buddha

Planned End Date: 31/12/2025

Local ref: 5603

The “SPEEDY Trial” is a randomized controlled trial aimed at evaluating a new pre-hospital pathway designed to enhance access to thrombectomy treatment. Thrombectomy is a time-sensitive surgical procedure that can significantly improve outcomes for stroke patients. However, this treatment is currently only available in larger regional hospitals, limiting its accessibility.

In the trial, some patients will receive care according to the new “SPEEDY” pathway, while others will continue to receive standard care. Ambulance stations and teams will be randomly assigned to either implement the SPEEDY pathway or continue with the usual standard of care. The trial is currently open in the WMAS region and is expected to expand to NWAS, SWASFT, and NEAS in the coming months. Its primary aim is to assess whether this new approach can improve access to thrombectomy treatment for stroke patients.

PI: Dr Rose Bosnell

Planned End Date: 30/11/2025

Local ref: 5404

The objective is to assess the clinical effectiveness of tranexamic acid (TXA) after stroke versus usual care. With the primary objective being assess the effect of TXA on early deaths and the secondary objective to assess the effect of TXA on          dependency 6 months after Intracerebral Haemorrhage (ICH). The team are measuring the cost effectiveness of TXA versus usual care. Incremental cost effectiveness ratios (ICERs), net monetary benefit and cost effectiveness of usual care versus TXA. HE data collection will include Health Care Resource Use and the EQ5D-5L.

PI: Dr Sandeep Buddha

Planned End Date: 01/08/2027

Local reg: 4756